FEATURED NEWS

FDA
October 13, 2017
FDA Approved changes to the Sustiva label, Genvoya, Norvir, Descovy and more. On October 12, 2017 the FDA approved changed to the Sustiva (efavienz) package insert to: Update information on hepatotoxicity in DOSAGE and ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSEREACTIONS and Patient Information sections. Update CONTRAINDICATIONS and MORE
MATEC
August 17, 2017
Adult and Adolescent Opportunistic Infections Guidlines Updated The following sections of the Guidelines for the Prevemtion and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently been updated: Hepatitis B Virus infection: This section was updated to include TAF/FTC as a treatment option for patients with HBV/HIV MORE
MATEC
August 1, 2017
Adult and Adolescent Opportunistic Infections Guidelines Updated July 28, 2017: The following sections of the Guidlines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently been updated: Click here to view recently updated guidlines Sections of the Pneumocystis guidlines have been MORE
FDA
June 21, 2017
FDA approves changes to the Kaletra label FDA approved changes to the Kaletra (lopinavir/ritonavir) tablet and oral solution labels. These changes include updates to the following sections: Section 2: DOSAGE and ADMINISTRATION with information about use of the oral solution with a feeding tube. 2.1 General Administration Recommendations Because MORE
MATEC
June 1, 2017
Updates to the Tuberculosis Section of the Adult and Adolescent Opportunistic Infections Guidelines May 18, 2017: The tuberculosis (TB) section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was recently updated. In this revision, the epidemiology, diagnosis, and treatment sections MORE